ARTICLE | Company News
Neurochem other research news
October 22, 2001 7:00 AM UTC
NRM received a $1.4 million grant from the FDA for NRM's ongoing Phase II/III study of Fibrillex to treat secondary amyloidosis, a systemic form of amyloidosis associated with deposition of amyloid pr...